Chronic myeloid leukemia data from India

Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010

Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008

Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010

Report of chronic myeloid leukemia from Indira Gandhi Institute of Medical Sciences, Regional Cancer Center, 2002-2009

Report of chronic myeloid leukemia in chronic phase from Eastern India, Institute of Hematology and Transfusion Medicine, Kolkata, 2001-2009

Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur

Report of chronic myeloid leukemia from SEAROC experience, Jaipur over a period of 9 years

Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital

A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh

The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad

Report of patients with chronic myeloid leukemia, from hematology clinic, Ahmedabad, Gujarat 2000-2010 at 1 st myelostone meeting: Indian evidence of chronic myelogenous leukemia

Report of patients with chronic myeloid leukemia Kidwai Memorial Institute of Oncology, Bangalore over 15 years

Report of chronic myeloid leukemia in chronic phase from Ashirwad Hematology Centre, Mumbai, 2002-2009

Report of chronic myeloid leukemia in chronic phase from Omega Hospital and Indo-American Centre, Hyderabad, 2004-2010

Report of chronic myeloid leukemia in chronic phase from Cancer Institute (Women India Association), Chennai, 2002-2009

Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009

Epidemiological and clinical profile of patients with chronic myeloid leukemia at Health-Care Global, Bangalore Institute of Oncology

Imatinib mesylate resistance and mutations: An Indian experience

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate

Therapeutic drug monitoring for imatinib: Current status and Indian experience